Skip to main content

Tagged With "clinical trial"

Survey

Understanding Clinical Research

AAFA Community Services ·
Please watch this video and answer the following questions. Your responses are anonymous. By answering these questions, you are participating in asthma research! Learn what clinical research is, who conducts research and who can participate. Watch video on YouTube Watch the next video in this series - Understanding Clinical Trials
Survey

Understanding Clinical Trials

AAFA Community Services ·
Please watch this video and answer the following questions. Your responses are anonymous. By answering these questions, you are participating in asthma research! Many people participate in clinical trials to help researchers find new treatments. Find out more about the four phases of clinical trials and their role in asthma research. Watch video on YouTube
Blog Post

AAFA Explains: Can Herbal Supplements Help My Nasal Allergies?

AAFA Community Services ·
When new drugs and medical procedures are developed, they go through rigorous scientific study. Complementary Alternative Medicine treatments usually do not go through the same type of research. As a result, whether it works (called efficacy) is unproven for most treatments. Most herbal remedies for rhinitis fall into that category.
Blog Post

AAFA Explains: Is Salt Therapy Safe and Effective for Asthma?

AAFA Community Services ·
In our second post in our “AAFA Explains” series, we look at claims that salt treatment (also known as halotherapy) can improve your asthma. “Salt rooms” are popping up in the U.S., Australia, the U.K. and elsewhere. These rooms charge you a fee to enter, like a spa. Salt crystals coat the rooms and the air is salt-laden as an attempt to mimic naturally occurring salt caves.The history of natural salt caves as an asthma remedy is ancient.
Blog Post

Asthma and Allergy Research Review, April-June 2017

AAFA Community Services ·
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Blog Post

Breathing in the Boat: The Turnaround Point

Megan Roberts ·
By Megan Roberts, Community Engagement Program Manager at the Asthma and Allergy Foundation of America This post is a follow up to Breathing in the Boat: Dragon Boat World Championships With Asthma . Paddling is my passion. I’ve raced boats in half of the world’s oceans, Hungary, Italy, Hawaii, Canada, Puerto Rico and all over the United States. I have not, however, ever had the opportunity before 2017 to race in China, the birthplace of the sport of dragon boating more than 2,500 years ago.
Blog Post Featured

Dr. Philip Norman: An AAFA Tribute to an Allergy Legend

AAFA Community Services ·
If you’ve ever benefited from immunotherapy (allergy shots, SLIT or oral immunotherapy), you can thank Dr. Philip Sidney Norman. Dr. Norman put allergy research on the map. He is known as the “father of modern immunotherapy for allergic disease” and even coined the term “allergen immunotherapy.” As an allergist and researcher for more than 50 years, he published 237 research papers and more than 100 book chapters and reviews. And for many decades, he was an important part of AAFA.
Blog Post

Dupilumab Shows Benefit for Those With Severe Asthma During Clinical Trial

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints.
Blog Post

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
Blog Post

FDA Approves a New Treatment Option for Those With Severe Asthma

AAFA Community Services ·
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Blog Post

FDA Approves Dupixent® for Treatment of Asthma

AAFA Community Services ·
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Blog Post

FDA Approves FASENRA® Pre-Filled Auto-Injector Pen for Self-Administration

AAFA Community Services ·
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).
Blog Post

FDA Approves First Seasonal Influenza Vaccine Containing an Adjuvant

AAFA Community Services ·
The U.S. Food and Drug Administration approved Fluad, the first seasonal influenza vaccine containing an adjuvant.
Blog Post

FDA Approves New Flu Treatment

AAFA Community Services ·
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Blog Post

FDA Approves Spiriva Respimat to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...
Blog Post

FDA Approves Symbicort to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Blog Post

FDA Approves Two New Asthma Inhalers

AAFA Community Services ·
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Blog Post

FDA Considers Biologic Dupilumab for Children Ages 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Blog Post

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AAFA Community Services ·
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post Featured

Help Others See Beyond Asthma and Allergies During National Asthma and Allergy Awareness Month

AAFA Community Services ·
Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. We also want to help people see beyond asthma and allergies. This year, we aim to do just that through our themes, “More Than Asthma” and “More Than Food Allergies.”
Blog Post

Poverty Widens Gap in Care for Asthma and Allergies

AAFA Community Services ·
Press Release Contact: Melissa Graham mgraham@aaaai.org (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
Blog Post

Promacta® Oral Suspension Recalled for Possible Peanut Contamination

AAFA Community Services ·
Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.
Blog Post

Teva Announces FDA Approval of QVAR® RediHaler™ Inhaler

AAFA Community Services ·
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Blog Post

Teva Launches AirDuo™ RespiClick® and its Authorized Generic

AAFA Community Services ·
[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...
Blog Post

Understanding Asthma Research: Get Involved

AAFA Community Services ·
Asthma research methods have been changing during the past several years. Research is more effective when researchers and patients work together to better understand asthma and find new treatments. At the Asthma and Allergy Foundation of America (AAFA), we feel your voice is valuable in asthma research. We support efforts to help you be an active part of the future of asthma management and treatments.
Blog Post

Living With Asthma in Birmingham, Alabama, the #8 Asthma Capital

AAFA Community Services ·
For many, asthma is caused by an allergic reaction to something. This is called allergic asthma is the most common. But a small number of people with asthma have “non-allergic asthma.” Lynn Johnson is part of this group. Lynn developed non-allergic asthma seven years ago, as an adult.
Blog Post

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

AAFA Community Services ·
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Blog Post

Omalizumab Makes Oral Immunotherapy Treatments More Effective

AAFA Community Services ·
Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.
Comment

Re: AAFA Explains: Is Salt Therapy Safe and Effective for Asthma?

K8sMom2002 ·
Hugs, Msshale68! It sounds like you have definitely had a frustrating time. Have you checked out AAFA's blog post about What to Do If You Can't Afford Your Asthma Medications ? You may be eligible for other help as well - AAFA has a list of other patient assistance programs, . Could you talk to your doctor about both the trouble you're having affording medications? You could also talk about whether it would be right for your particular health situation to do a trial of the salt therapy to...
Survey

Understanding Asthma and How Patients Can Guide Research (Full-Length)

AAFA Community Services ·
Please watch this video and answer the following questions. Your responses are anonymous. By answering these questions, you are participating in asthma research! This video compilation is 37:20 long and includes all of our project's episodes in one video. If you would rather watch shorter episodes, find them on Why Patient Engagement in Asthma Research Is Important . As you watch the video series, take notes using the Asthma Patient-Centered Research Training Guide . Watch video on YouTube
Blog Post

Asthma and Allergy Research With You as an Equal Partner

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) conducts and promotes patient-centered research to help you. This means your beliefs, preferences and needs are at the center of our research. Your input drives our advocacy work, guides our education programs and supports our community. Recently, we’ve studied the following topics: Symptoms of anaphylaxis in infants and toddlers Eczema burdens and people’s experiences with treatments Impact of COVID-19 on people with asthma and allergy Air...
Blog Post

FDA Approves Dupixent® (Dupilumab) for Children Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

AAFA Community Services ·
The U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic medicine approved for this patient population.
Blog Post

Town Hall: Black Americans and the COVID-19 Vaccine

AAFA Community Services ·
The COVID-19 pandemic has hit Black Americans hard. According to The COVID Racial Data Tracker , the COVID death rate of Black Americans is 1.5 times that of white people. We now have two COVID-19 vaccines , with more on the way. While the vaccines offer hope overall, they raise other concerns. Many Black Americans may not be able to get it. Or they may choose to not to get it. The National Minority Quality Forum (NMQF) held a virtual town hall on Jan. 25, 2021, to examine barriers that may...
Blog Post

FDA Approves Xolair® (Omalizumab) Prefilled Syringe for Self-Injection

AAFA Community Services ·
Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Blog Post

Amgen Submits Biologics License Application for Tezepelumab for Severe Asthma

AAFA Community Services ·
Amgen today announced its partner AstraZeneca submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.
Blog Post

Dupixent® (Dupilumab) Improves Lung Function and Reduces Asthma Attacks in Children in Phase 3 of Clinical Trial

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) is sharing this press release to bring you the latest research news quickly. [PRESS RELEASE] Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for...
Blog Post

Help Improve and Save Lives by Driving the Future of Asthma and Allergy Research

AAFA Community Services ·
Research has brought us amazing medical discoveries and treatments. But research is also a continual process if we are to pursue better health. Asthma and allergies are complex conditions. Research gives us a better understanding of them. This can lead to new medicines, ways to improve quality of life, and hopefully, cures. And research can be most effective when it centers around the qualities and needs of the patients it aims to serve. The Asthma and Allergy Foundation of America (AAFA)...
Comment

Re: Help Improve and Save Lives by Driving the Future of Asthma and Allergy Research

mdashiquennobi ·
Wish in near future I can involve myself with asthma research and also share my experience as a patient.
Comment

Re: Help Improve and Save Lives by Driving the Future of Asthma and Allergy Research

Melanie Carver ·
Thank you @mdashiquennobi ! Please be sure your AAFA member profile is up to date . When research studies come up that may match your profile information, we will send the opportunity to you via email. Also keep an eye on our blog where we publish surveys that are open to our members to join in. You can change your notifications so that you receive an email every time we add a new blog. Thanks so much for contributing to asthma research!
Blog Post

FDA Issues Statement on Steps They Will Take to Ensure COVID-19 Vaccines Are Safe and Effective for Young Children

AAFA Community Services ·
As regulators, the FDA recognizes they have an important task ahead of them that will require them to act expeditiously while undertaking an extremely meticulous and thoughtful review once we receive requests to authorize a COVID-19 vaccine for emergency use or submissions for approval of a COVID-19 vaccine for this population.
×
×
×
×